FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Home Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced today that JPMorgan, the underwriters of the Company’s recent initial public offering, have exercised their over-allotment option to purchase 989,923 additional shares of common stock from certain selling stockholders at the public offering price of $12 per share. The over-allotment option was granted to the underwriters by certain of the selling stockholders and Home Diagnostics, Inc. will not issue any new shares of common stock or receive any proceeds from the sale of these shares.
